Ideaya Biosciences (IDYA) provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2-negative metastatic uveal melanoma. The database lock is projected in the first half of April, followed by the topline data analysis thereafter. A live investor and analyst webcast will be hosted by Ideaya management and a guest key opinion leader, the company said.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences falls -6.0%
- IDEAYA Biosciences: Operational Trial Delay but High Conviction Buy Ahead of Key Darovasertib Readout
- IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating
- Ideaya Biosciences enrolls first patient in IDE892 trial
- Citi opens ‘upside 90-day catalyst watch’ on Ideaya Biosciences